Aperion Biologics
Stage
Corporate Minority | AliveTotal Raised
$7MAbout Aperion Biologics
Aperion Biologics is a clinical-stage medical device company addressing the need for alternatives to human-based grafts with patented animal based tissue. Aperion Biologics has developed and patented a technique to make animal tissues usable for human applications without causing rejection. The core platform technology is an enzymatic stripping of the key carbohydrate antigens followed by a unique conversion process that both "humanizes" and sterilizes the tissues without affecting the biomechanical or biological properties. This tissue scaffold provides mechanical stability and function while being biologically integrated and remodeled. Aperion's Z-Process of humanizing and sterilizing tissue can be applicable to a variety of tissues from orthopedic ligaments, bone, and meniscus to valves and vessels to soft tissue grafts for augmentation and repair.
Missing: Aperion Biologics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Aperion Biologics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Aperion Biologics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aperion Biologics is included in 3 Expert Collections, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Medical Devices
8,633 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,901 items
Aperion Biologics Patents
Aperion Biologics has filed 1 patent.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
8/9/2004 | 1/12/2010 | Cardiac surgery, Transcription factors, Valvular heart disease, Cardiac surgeons, Implants (medicine) | Grant |
Application Date | 8/9/2004 |
---|---|
Grant Date | 1/12/2010 |
Title | |
Related Topics | Cardiac surgery, Transcription factors, Valvular heart disease, Cardiac surgeons, Implants (medicine) |
Status | Grant |
Latest Aperion Biologics News
Dec 7, 2017
Advertisement Privately-held Aperion Biologics (FDBA Crosscart) filed for Chapter 7 protection with the U.S. Bankruptcy Court in the District of Delaware, case number 17-12855. According to BankruptcyData, under a Chapter 7 proceeding, “generally assets are sold by a trustee and the company ceases operation.” Advertisement Aperion is located in San Antonio, Texas, and is presently headed by interim C.F.O. The Company is represented in these proceedings by David M. Klauder of Bielli & Klauder. Aperion Biologics is a commercial-stage medical device company that addresses the significant need for alternatives to human-based sources for tissues to be used in surgical procedures. According to its website, the Company’s lead product, with 14 patents worldwide, is Z-Lig (Reg. ): “an alternative knee ligament reconstruction tissue that is designed to be better for patients and better for surgeons.” According to Court filings, Aperion indicates estimates liabilities at $10 to $50 million, with estimated assets of just $100,000 to $500,000.
Aperion Biologics Frequently Asked Questions (FAQ)
Where is Aperion Biologics's headquarters?
Aperion Biologics's headquarters is located at 11969 Starcrest Drive, San Antonio.
What is Aperion Biologics's latest funding round?
Aperion Biologics's latest funding round is Corporate Minority.
How much did Aperion Biologics raise?
Aperion Biologics raised a total of $7M.
Who are the investors of Aperion Biologics?
Investors of Aperion Biologics include Vienna Insurance Group, Lurie Investment Fund, HealthpointCapital and Deutsche Bank.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.